FDA shoots down Spec­trum's neu­trope­nia drug, cit­ing man­u­fac­tur­ing is­sues

In an­oth­er set­back for Spec­trum Phar­ma­ceu­ti­cals, the FDA has re­ject­ed its lead drug for neu­trope­nia in pa­tients re­ceiv­ing can­cer drugs.

The com­pa­ny said Fri­day the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER